By Dr David Robert Croucher

Journal articles

Fey D; Croucher DR; Kolch W; Kholodenko BN, 2012, 'Crosstalk and signaling switches in mitogen-activated protein kinase cascades', Frontiers in Physiology, 3 SEP, http://dx.doi.org/10.3389/fphys.2012.00355

Daly RJ; Hochgraefe F; Croucher DR; Zhang L; Rickwood D; Browne BC; Tactacan C; Raftery M, 2011, 'A novel tyrosine kinase signaling pathway in human basal breast cancer', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-3131

Cochran BJ; Saunders D; Croucher DR; Lobov S; Ranson M, 2011, 'Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of serpinE1 and serpinB2 in cancer', The Journal of Biological Chemistry, 286, pp. 24467 - 24475, http://dx.doi.org/10.1074/jbc.M111.225706

Lee JA; Croucher DR; Ranson M, 2010, 'Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes', Thrombosis and Haemostasis, 104, pp. 1133 - 1142, http://dx.doi.org/10.1160/TH10-02-0121

Croucher D; Ranson M; Saunders D, 2010, 'SerpinB2', AfCS-Nature Molecule Pages, http://dx.doi.org/10.1038/mp.a004139.01

Croucher DR; Rickwood D; Tactacan C; Musgrove EA; Daly RJ, 2010, 'Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells', Molecular and Cellular Biology, 30, pp. 5057 - 5070, http://dx.doi.org/10.1128/MCB.00249-10

Fleuren E; O'Toole S; Millar E; Mcneil CM; Lopez-Knowles E; Boulghourjian A; Croucher DR; Schramek D; Brummer T; Penninger JM; Sutherland RL; Daly RJ, 2010, 'Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development', International Journal of Cancer, 127, pp. 1486 - 1492

Hochgrafe F; Zhang L; O'Toole S; Browne BC; Pinese M; Porta cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ, 2010, 'Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells', Cancer research, 70, pp. 9391 - 9401, http://dx.doi.org/10.1158/0008-5472.CAN-10-091

Abdipranoto-Cowley A; Jin SP; Croucher DR; Daniel JA; Henshall SM; Galbraith SA; Mervin K; Vissel B, 2009, 'Activin A is essential for neurogenesis following neurodegeneration', Stem Cells, 27, pp. 1330 - 1346

Samson AL; Nevin ST; Croucher D; Niego B; Daniel PB; Weiss TW; Moreno E; Monard D; Lawrence DA; Medcalf RL, 2008, 'Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function', Journal of Neurochemistry, 107, pp. 1091 - 1101, http://dx.doi.org/10.1111/j.1471-4159.2008.05687.x

Lobov S; Croucher DR; Saunders DN; Ranson M, 2008, 'Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: Potential receptor interactions', Thrombosis and Haemostasis, 100, pp. 319 - 329, http://dx.doi.org/10.1160/TH08-02-0119

Croucher DR; Saunders DN; Lobov S; Ranson M, 2008, 'Revisiting the biological roles of PAI2 (SERPINB2) in cancer', Nature Reviews Cancer, 8, pp. 535 - 545, http://dx.doi.org/10.1038/nrc2400

Cao XR; Lill NL; Boase N; Shi PP; Croucher DR; Shan H; Qu J; Sweezer EM; Place T; Kirby PA; Daly RJ; Kumar S; Yang B, 2008, 'NEDD4 controls animal growth by regulating IGF-1 signalling', Sci Signal. 2008 Oct 14;1(41):ra8., 1, pp. 1 - 10

Lobov S; Croucher DR; Saunders DA; Ranson M, 2008, 'Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro', Journal of Thrombosis and Haemostasis, 100, pp. 319 - 329

Croucher DR; Saunders DM; Stillfried GE; Ranson M, 2007, 'A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells', Biochemical Journal, 408, pp. 203 - 210, http://dx.doi.org/10.1042/BJ20070767

Stutchbury T; Al-ejeh F; Stillfried G; Croucher DR; Andrews JG; Irving D; Links MR; Ranson M, 2007, 'Preclinical evaluation of Bi-213-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma', Molecular Cancer Therapeutics, 6, pp. 203 - 212

Croucher D; Saunders DN; Ranson M, 2006, 'The urokinase/PAI-2 complex: A new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein', Journal of Biological Chemistry, 281, pp. 10206 - 10213, http://dx.doi.org/10.1074/jbc.M513645200

Croucher D; Saunders D; Leung H; Ranson M, 2006, 'ID: 131 A structural basis for differential cell signaling initiated by PAI-1 and PAI-2: Implications for Metastatic Potential', Journal of Thrombosis and Haemostasis, 4, pp. 197 - 197, http://dx.doi.org/10.1111/j.1538-7836.2006.00131.x

Lobov S; Croucher D; Ranson M, 2006, 'ID: 138 Assessment of known/potential binding sites in the PAI-2 CD-loop for interaction with annexin II and endocytosis receptors', Journal of Thrombosis and Haemostasis, 4, pp. 198 - 198, http://dx.doi.org/10.1111/j.1538-7836.2006.00138.x

Samson A; Niego B; Daniel P; Weiss T; Croucher D; Lawrence D; Medcalf R, 2006, 'ID: 200 Tissue-type plasminogen activator can promote NMDA-induced neuronal stimulation via LDL receptor and plasmin-dependent mechanisms.', Journal of Thrombosis and Haemostasis, 4, pp. 139 - 139, http://dx.doi.org/10.1111/j.1538-7836.2006.00200.x

Al-Ejeh F; Croucher D; Ranson M, 2004, 'Kinetic analysis of plasminogen activator inhibitor type-2: Urokinase complex formation and subsequent internalisation by carcinoma cell lines', Experimental Cell Research, 297, pp. 259 - 271, http://dx.doi.org/10.1016/j.yexcr.2004.03.030

Conference Papers

Kolch W; Fey D; Halasz M; Rauch N; Munoz AG; Pilkington R; Kholodenko BN; Croucher DR; Kennedy SP; Hastings JF; Westermann F; Dreidax D; Fischer M; Duffy D; Krstic A; Schwarzl T, 2015, 'Abstract CN05-03: Personalized cancer diagnostics and therapeutics based on the computational modeling of signal transduction networks', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1535-7163.targ-15-cn05-03

Liu L; Chan H; Croucher D; Hochgraefe F; Zhang L; Tactacan C; Daly R, 2013, 'Mechanistic and functional characterization of the atypical kinase SgK269/PEAK1 in breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-2507

Preprints

Walter S; Ho J; Alvarado R; Smith G; Croucher DR; Liang S; Es SLV; Earls P; Rimmer J; Campbell R; Kalish L; Sacks R; Harvey R, 2024, Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis, , http://dx.doi.org/10.22541/au.170669863.35814827/v1

Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., , http://dx.doi.org/10.21203/rs.3.rs-1789675/v1

Trevelyan SJ; Brewster JL; Burgess AE; Crowther JM; Cadell AL; Parker BL; Croucher DR; Dobson RCJ; Murphy JM; Mace PD, 2019, Mechanism of preferential complex formation by Apoptosis Signal-regulating Kinases, , http://dx.doi.org/10.1101/693663

Hastings J; Gonzalez-Rajal A; Han JZR; McCloy R; O’Donnell YEI; Phimmachanh M; Murphy A; Nagrial A; Daneshvar D; Chin V; Watkins N; Burgess A; Croucher D, 2019, Dynamic analysis of pulsed cisplatin identifies effectors of resistance in lung adenocarcinoma, , http://dx.doi.org/10.1101/775924

Back to profile page